This federal contract award to Colorado State University, a public land-grant university, is to develop and manufacture an inactivated virus vaccine using blood pathogen reduction technology to address COVID-19. The award, valued at $19,218,003, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under a broader NIAID Omnibus Broad Agency Announcement for advanced development of vaccine candidates and therapeutics for biodefense and emerging infectious diseases. The contract does not utilize any set-aside designations. Major subcontractors supporting the vaccine development effort include Charles River Laboratories, Fisher Scientific, Bioreliance Corporation, and 10X Genomics. This award aligns with NIAID's mission to advance biomedical research to understand, treat, and prevent infectious diseases.
Generated 3/16/25, 12:43 AM